1. Tsai T-F, Lee C-H, Huang Y-H, et al. Taiwanese Dermatological Association consensus statement on management of psoriasis. Dermatologica Sinica 2017;
35(2): 66-77.
2. National Institute for Health and Care Excellence. Psoriasis: assessment and management. https://www.nice.org.uk/guidance/cg153. Published 2017. Accessed June 26, 2018.
3. Tsai TF, Wang TS, Hung ST, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. Journal of dermatological science 2011;
63(1): 40-46.
4. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. Journal of the American Academy of Dermatology 2011; 65(1):
137-174.
5. Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. The British journal of
dermatology 2017; 177(3): 628-636.
6. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2018. https://www.whocc.no/atc_ddd_index/. Accessed June 15, 2018.
7. 衛生福利部食品藥物管理署. 西藥、醫療器材、含藥化粧品許可證查詢.
https://www.fda.gov.tw/MLMS/H0001.aspx. Accessed June 15, 2018.
8. 衛生福利部中央健康保險署. 健保用藥品項查詢.
https://www.nhi.gov.tw/QueryN/Query1.aspx. Accessed June 15, 2018.
9. 衛生福利部中央健康保險署. 全民健康保險藥物給付項目及支付標準共同擬 訂會議第 31 次加開臨時(107 年 5 月)會議紀錄(107.06.21 新增).
https://www.nhi.gov.tw/Content_List.aspx?n=C9AD7A30DC886EFA&topn=3FC 7D09599D25979. Published 2018. Accessed July 6, 2018.
10. 衛生福利部中央健康保險署. 全民健康保險藥品給付規定-107 年版.
https://www.nhi.gov.tw/Content_List.aspx?n=E70D4F1BD029DC37&topn=3FC 7D09599D25979. Accessed June 15, 2018.
11. Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with
moderate-to-severe plaque psoriasis. The British journal of dermatology 2016;
175(2): 273-286.
12. Lebwohl M, Strober B, Menter A, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. The New England journal of medicine 2015;
373(14): 1318-1328.
13. Canadian Agency for Drugs and Technologies in Health (CADTH). Brodalumab (Siliq — Valeant Canada LP). https://www.cadth.ca/brodalumab. Published 2016.
Accessed July 6, 2018.
14. National Institute for Health and Care Excellence. Brodalumab for treating moderate to severe plaque psoriasis. https://www.nice.org.uk/guidance/ta511.
Published 2018. Accessed June 26, 2018.
15. Scottish Medicines Consortium. brodalumab 210mg solution for injection in pre-filled syringe (Kyntheum® ).
https://www.scottishmedicines.org.uk/medicines-advice/brodalumab-kyntheum-re submission/. Published 2018. Accessed June 27, 2018.
16. Yamasaki K, Nakagawa H, Kubo Y, Ootaki K. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. The British journal of dermatology 2017;
176(3): 741-751.
17. Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. Journal of the American Academy of
Dermatology 2014; 71(6): 1183-1190.e1183.
18. Nakagawa H, Niiro H, Ootaki K. Brodalumab, a human
anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study. Journal of dermatological science 2016; 81(1):
44-52.
19. Umezawa Y, Nakagawa H, Niiro H, Ootaki K. Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with
moderate-to-severe plaque psoriasis. Journal of the European Academy of
Dermatology and Venereology : JEADV 2016; 30(11): 1957-1960.
20. Papp KA, Gordon KB, Langley RG, et al. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with
moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. The British journal of
dermatology 2018; 172(2): 320-328.
21. de Carvalho AV, Duquia RP, Horta BL, Bonamigo RR. Efficacy of
Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Drugs in R&D 2017;
17(1): 29-51.
22. Bilal J, Berlinberg A, Bhattacharjee S, Trost J, Riaz IB, Kurtzman DJB. A Systematic Review and Meta-Analysis of the Efficacy and Safety of the
Interleukin (IL)-12/23 and IL-17 Inhibitors Ustekinumab, Secukinumab,
Ixekizumab, Brodalumab, Guselkumab, and Tildrakizumab for the Treatment of Moderate to Severe Plaque Psoriasis. The Journal of dermatological treatment 2018: 1-37.
23. Sawyer L, Fotheringham I, Wright E, Yasmeen N, Gibbons C, Holmen Moller A.
The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. The Journal
of dermatological treatment 2018: 1-12.
24. Loos AM, Liu S, Segel C, Ollendorf DA, Pearson SD, Linder JA. Comparative effectiveness of targeted immunomodulators for the treatment of
moderate-to-severe plaque psoriasis: A systematic review and network
meta-analysis. Journal of the American Academy of Dermatology 2018; 79(1):
135-144.e137.
25. Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological
treatments for chronic plaque psoriasis: a network meta-analysis. The Cochrane
database of systematic reviews 2017; 12: Cd011535.
26. Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. The British journal of dermatology 2017; 177(1):
47-62.
27. Feldman SR, Rastogi S, Lin J. Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-to-Severe Psoriasis in the United States. Dermatology and therapy 2018: 1-13.
28. Wu JJ, Feldman SR, Rastogi S, Menges B, Lingohr-Smith M, Lin J. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. Journal of Dermatological Treatment 2018: 1-6.
29. Feldman SR, Wu JJ, Rastogi S, Menges B, Lingohr-Smith M, Lin J. The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans. Journal of medical economics 2018; 21(5):
537-541.
30. 衛生福利部統計處. 104 年度全民健康保險醫療統計年報.
https://dep.mohw.gov.tw/DOS/np-1919-113.html. Accessed July 4 2018.
31. Chen K-C, Hung S-T, Yang C-WW, Tsai T-F, Tang C-H. The economic burden of psoriatic diseases in Taiwan. Journal of dermatological science 2014; 75(3):
183-189.
32. Chang Y-T, Chen T-J, Liu P-C, et al. Epidemiological study of psoriasis in the national health insurance database in Taiwan. Acta dermato-venereologica 2009;
89(3): 262-266.
33. Tsai T-F, Wang T-S, Hung S-T, et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. Journal of dermatological science 2011;
63(1): 40-46.
34. Wang T-S, Hsieh C-F, Tsai T-F. Epidemiology of psoriatic disease and current treatment patterns from 2003 to 2013: a nationwide, population-based
observational study in Taiwan. Journal of dermatological science 2016; 84(3):
340-345.
35. Wei JC-C, Shi L-H, Huang J-Y, Wu X-F, Wu R, Chiou J-Y. Epidemiology and Medication Pattern Change of Psoriatic Diseases in Taiwan from 2000 to 2013: A Nationwide, Population-based Cohort Study. The Journal of Rheumatology 2018;
45(3):385-392.
36. 衛生福利部中央健康保險署. 全民健康保險藥物給付項目及支付標準共同擬 訂會議第 31 次加開臨時(107 年 5 月)會議紀錄.
https://www.nhi.gov.tw/Content_List.aspx?n=C9AD7A30DC886EFA&topn=3FC 7D09599D25979. Published 107. Accessed July 4, 2018.
附錄
附錄一 療效評估文獻搜尋記錄
資料庫 查詢日期 關鍵字 篇數 篩選後篇數
PubMed 2018.06.21
#1 psoriasis
#2 brodalumab
#1 AND #2
142 13
EMBASE 2018.06.21
#1 psoriasis
#2 brodalumab
#1 AND #2
519 0*
Cochrane
Library 2018.06.21
#1 psoriasis
#2 brodalumab
#1 AND #2
53 0*
* 去除與 PubMed 資料庫重複之文獻。
附錄二 經濟評估文獻搜尋記錄
資料庫 查詢日期 關鍵字 篇數
PubMed 2018.07.24 1 "brodalumab"[Supplementary Concept] OR
"brodalumab"[All Fields]
179 2 "economics"[Subheading] OR
"economics"[All Fields] OR "cost"[All Fields]
OR "costs and cost analysis"[MeSH Terms]
OR ("costs"[All Fields] AND "cost"[All Fields] AND "analysis"[All Fields]) OR "costs and cost analysis"[All Fields]
765,955
3 #1 and #2 4
Cochrane Library
2018.07.24 1 brodalumab (Economic evaluations) 0 CRD 2018.07.24 1 ((brodalumab)) and ((Economic
evaluation:ZDT and Bibliographic:ZPS) OR (Economic evaluation:ZDT and Abstract:ZPS) OR Project record:ZDT OR Full publication record:ZDT) IN NHSEED, HTA
2